BeOne Medicines commits $300m to expand New Jersey manufacturing

CE2026-07-23T14:30:00

Source:

Facility expansion combines biologics and small molecule drug product manufacturing under one roof to accelerate its haematology and oncology pipeline.

eOne Medicines is investing $300 million to expand its flagship manufacturing and research and development (R&D) centre in New Jersey, US. The decision will support greater production capacity and BeOne’s oncology pipeline.

It brings the firm’s total manufacturing investment in Hopewell to over $1 billion.

The new Princeton West Innovation Campus building in Hopewell will house drug product manufacturing and packaging operations to help build BeOne’s haematology portfolio and pipeline, alongside quality control laboratories…

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

Unlimited access to industry intelligence that can make a difference to your business
A weekly newsletter keeping the most vital information at the front of your thinking
Exclusive invitations to powerful webinars and events featuring high profile experts
Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member